22 completed, 6 terminated, 1 recruiting, 1 withdrawn. 14 Phase 4, 8 Phase 2, 5 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 8, Terminated 4, Recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 7, Terminated 1 |
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow argatroban: new trials by email Literature Review of argatroban trials Research Report on argatroban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support Enoxaparin Injectable Solution, Argatroban, 1 Mg/mL Intravenous Solution, Unfractionated heparin - Respiratory Insufficiency, Circulatory Failure | Phase 4 | Recruiting | Medical University of Vienna | 90 | 2024-07-30 | 2024-10-29 |
| A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects VLX-1005, Argatroban - Heparin-induced Thrombocytopenia | Phase 1 | Completed | Veralox Therapeutics | 12 | 2022-03-07 | 2023-01-11 |
| Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO Argatroban, Unfractionated heparin - Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 40 | 2021-12-01 | 2024-09-19 |
| Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO Argatroban, unfractionated heparin - Respiratory Failure | Not applicable | Completed | Beijing Chao Yang Hospital | 20 | 2021-07-06 | 2024-03-26 |
| Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Enoxaparin sodium, Unfractionated heparin, Fondapariniux - COVID-19 | Phase 4 | Terminated | Weill Medical College of Cornell University | 14 | 2020-10-13 | 2023-09-21 |
| Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure Argatroban Injection, Heparin - ARDS, COVID-19 | Completed | University Hospital Ostrava | 100 | 2020-04-01 | 2024-03-01 | |
| Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE) Argatroban - Acute Progressive Ischemic Stroke | Phase 4 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 628 | 2020-03-21 | 2023-04-19 |
| Multi-arm Optimization of Stroke Thrombolysis Argatroban, Eptifibatide, Placebo - Acute Ischemic Stroke | Phase 3 | Completed | Washington University School of Medicine | 514 | 2019-10-15 | 2025-02-07 |
| Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban Danaparoid Sodium, Argatroban - Heparin-induced Thrombocytopenia | Phase 3 | Terminated | Aspen Global Incorporated | 7 | 2019-05-16 | 2022-12-08 |
| Argatroban Plus R-tPA for Acute Ischemic Stroke rt-PA, Argatroban - Stroke | Phase 4 | Completed | General Hospital of Shenyang Military Region | 808 | 2018-12-21 | 2022-02-22 |
| Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke Argatroban plus dual antiplatelet - Stroke, Ischemic | Phase 4 | Completed | General Hospital of Shenyang Military Region | 120 | 2017-10-25 | 2020-07-22 |
| Safety of Argatroban Infusion in Conduction Disturbances Argatroban - Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative) | Phase 4 | Completed | Tanabe Pharma GmbH | 50 | 2017-04-18 | 2025-12-30 |
| Thromboprophylaxis After Surgery for Gynecologic Malignancy in China s-LMWH, LMWH, Argatroban - Gynecologic Neoplasms, Venous Thromboembolism | Phase 3 | Completed | Huazhong University of Science and Technology | 315 | 2016-01-01 | 2019-05-14 |
| Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke Argatroban - Stroke, Cerebral Ischemia | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 10 | 2015-05-01 | 2017-06-21 |
| Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia direct thrombin inhibition, enoxaparin - Staphylococcus Aureus Bacteraemia | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 94 | 2013-01-01 | 2016-07-13 |
| Argatroban in Critically Ill Patients With Heparin Resistance Argatroban - Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance | Phase 2 | Completed | Medical University Innsbruck | 44 | 2012-07-29 | 2017-11-17 |
| Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase) - Ischemic Stroke | Phase 2 | Terminated | Andrew D. Barreto, MD | 90 | 2011-10-01 | 2017-05-11 |
| Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Argatroban and warfarin - Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody | Phase 4 | Terminated | Massachusetts General Hospital | 9 | 2010-11-01 | 2017-11-17 |
| Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting Argatroban, non-argatroban treated group - CVD | Phase 4 | Completed | Jinling Hospital, China | 114 | 2010-08-01 | 2015-11-23 |
| Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting Argatroban, non-argatroban treated group - CVD | Phase 4 | Completed | Xinfeng Liu | 114 | 2010-04-01 | 2015-10-23 |
Showing 20 of 30. Sign in to see all of them.
Ischemic Stroke (4) · Stroke (4) · Angina, Unstable (2) · COVID-19 (2) · Hemorrhage (2) · Respiratory Insufficiency (2) · Thrombocytopenia (2) · Thrombosis (2) · Acute Coronary Syndrome (1) · Acute Lung Injury (1) · Bites and Stings (1) · Brain Ischemia (1) · Coronary Artery Disease (1) · Genital Neoplasms, Female (1) · Hemostatic Disorders (1)
General Hospital of Shenyang Military Region (2) · Medical University of Vienna (2) · Tanabe Pharma Corporation (2) · The University of Texas Health Science Center, Houston (2) · Andrew D. Barreto, MD (1) · Aspen Global Incorporated (1) · Beijing Chao Yang Hospital (1) · Canyon Pharmaceuticals, Inc. (1) · Encysive Pharmaceuticals (1) · GlaxoSmithKline (1) · Heinrich-Heine University, Duesseldorf (1) · Huazhong University of Science and Technology (1) · Jinling Hospital, China (1) · Massachusetts General Hospital (1) · Medical University Innsbruck (1)
United States (11) · China (7) · Germany (4) · Austria (3) · Belgium (2) · France (2) · Bosnia and Herzegovina (1) · Canada (1) · Czechia (1) · Italy (1) · Japan (1) · Poland (1) · Russia (1) · Serbia (1)
Xinfeng Liu, MD (2) · Allen Hunt, MBA (1) · Andrew Barreto, MD (1) · Andrew D Barreto, MD, MS (1) · Andrew D. Barreto, MD (1) · Bing Sun, MD (1) · Bob L Lobo, Pharm.D. (1) · Dawn Bell, PharmD (1) · Ding Ma, M.D. (1) · Huisheng Chen, Doctor (1)
PMID 16908730, PMID 20226548, PMID 20435232, PMID 21079512, PMID 22223235, PMID 25344113, PMID 26556106, PMID 28507269, PMID 29169470, PMID 29426286, PMID 32244368, PMID 32485328, PMID 33297893, PMID 33314078, PMID 35244208, PMID 36757755, PMID 37256980, PMID 38190136, PMID 39231343, PMID 40123511, PMID 40396972, PMID 40635702, PMID 40824660, PMID 41071964, PMID 41678142
2016 (1), P50NS044227 (1), U01NS100699 (1)